Advances in the Elimination of Viral Hepatitis in Mexico: A Local Perspective on the Global Initiative DOI Creative Commons
Gerardo Santos‐López, Arturo Panduro, Francisca Sosa-Jurado

et al.

Pathogens, Journal Year: 2024, Volume and Issue: 13(10), P. 859 - 859

Published: Oct. 1, 2024

Viral hepatitis (A–E) presents a major global health challenge. In 2015, the World Health Organization (WHO) launched an initiative to eliminate viral hepatitis, with aim of reducing new infections by 90% and deaths 65% 2030. Mexico is one 38 focus countries identified WHO, collectively accounting for 80% deaths. While B C are commonly diagnosed in Mexico, routine diagnosis D E lacking, no specific epidemiological data available. 2020, implemented National Hepatitis Elimination Program, focusing on preventing infections, complications like cirrhosis hepatocellular carcinoma, ensuring access treatment, improving patient care. However, this program has not been extended E. Addressing challenges control requires increased resource allocation, expanded diagnosis, vaccination A B, treatment coverage C, along multisectoral engagement. This work provides overview Mexico’s response initiative, highlighting its progress, challenges, areas opportunity.

Language: Английский

Development of Virus-Like Particles (VLPs) for Hepatitis C Virus genotype 4: a novel approach for vaccine development in Egypt DOI Creative Commons

Ahmed Ali,

Rasha A.M. Azouz, Nahla A. Hussein

et al.

BMC Biotechnology, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 18, 2025

Abstract Background Egypt has the highest global prevalence of Hepatitis C Virus (HCV) infection, particularly genotype 4. The development a prophylactic vaccine remains crucial for HCV eradication, yet no such currently exists due to challenges. ability Virus-Like Particles (VLPs) mimic native virus and incorporate neutralizing conformational epitopes, while effectively engaging both humoral cellular immune responses, makes them promising approach addressing challenges in development. Methods Lentiviral-based vectors were constructed employed integrate full-length sequence Core, E1, E2, P7 genes 4 into genome Human Embryonic Kidney cells (HEK293T). Upon expression, structural proteins can oligomerize self-assemble VLPs mimicking structure virus. purified characterized potential VLPs-based vaccine. Results In this study, mammalian successfully engineered stably express generate non-infectious expression HCV-integrated resulted successful production proteins, which oligomerized self-assembled two layers enveloped VLPs. Electron microscopy analysis revealed spherical particles with an average diameter 60–65 nm, closely resembling mature virions. These results highlighted these as candidate Conclusions underexplored target development, despite its significant public health burden, especially Egypt. generation represents avenue further established system provides robust platform study VLP-based vaccines targeting

Language: Английский

Citations

1

A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV) DOI
Kajal Sharma, Meesala Krishna Murthy

European Journal of Clinical Microbiology & Infectious Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: March 22, 2025

Language: Английский

Citations

0

Unlocking Potential: Virus-Like Particles as a Promising Strategy for Effective HCV Vaccine Development DOI
Saleh A. Mohamed, Ashraf A. Tabll

Virology, Journal Year: 2024, Volume and Issue: 602, P. 110307 - 110307

Published: Nov. 15, 2024

Language: Английский

Citations

1

Advances in the Elimination of Viral Hepatitis in Mexico: A Local Perspective on the Global Initiative DOI Creative Commons
Gerardo Santos‐López, Arturo Panduro, Francisca Sosa-Jurado

et al.

Pathogens, Journal Year: 2024, Volume and Issue: 13(10), P. 859 - 859

Published: Oct. 1, 2024

Viral hepatitis (A–E) presents a major global health challenge. In 2015, the World Health Organization (WHO) launched an initiative to eliminate viral hepatitis, with aim of reducing new infections by 90% and deaths 65% 2030. Mexico is one 38 focus countries identified WHO, collectively accounting for 80% deaths. While B C are commonly diagnosed in Mexico, routine diagnosis D E lacking, no specific epidemiological data available. 2020, implemented National Hepatitis Elimination Program, focusing on preventing infections, complications like cirrhosis hepatocellular carcinoma, ensuring access treatment, improving patient care. However, this program has not been extended E. Addressing challenges control requires increased resource allocation, expanded diagnosis, vaccination A B, treatment coverage C, along multisectoral engagement. This work provides overview Mexico’s response initiative, highlighting its progress, challenges, areas opportunity.

Language: Английский

Citations

0